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Trastuzumab,	a	monoclonal	antibody	targeting	human	epidermal	growth	factor	receptor	2	(HER2;	also	known	
as	HER-2/neu),	is	indicated	for	the	treatment	of	women	with	either	early	stage	or	metastatic	HER2+	breast	
cancer.	It	kills	tumor	cells	by	several	mechanisms,	including	antibody-dependent	cellular	cytotoxicity	(ADCC).	
Strategies	that	enhance	the	activity	of	ADCC	effectors,	including	NK	cells,	may	improve	the	efficacy	of	trastu-
zumab.	Here,	we	have	shown	that	upon	encountering	trastuzumab-coated,	HER2-overexpressing	breast	can-
cer	cells,	human	NK	cells	become	activated	and	express	the	costimulatory	receptor	CD137.	CD137	activation,	
which	was	dependent	on	NK	cell	expression	of	the	FcγRIII	receptor,	occurred	both	in	vitro	and	in	the	periph-
eral	blood	of	women	with	HER2-expressing	breast	cancer	after	trastuzumab	treatment.	Stimulation	of	trastu-
zumab-activated	human	NK	cells	with	an	agonistic	mAb	specific	for	CD137	killed	breast	cancer	cells	(including	
an	intrinsically	trastuzumab-resistant	cell	line)	more	efficiently	both	in	vitro	and	in	vivo	in	xenotransplant	
models	of	human	breast	cancer,	including	one	using	a	human	primary	breast	tumor.	The	enhanced	cytotoxicity	
was	restricted	to	antibody-coated	tumor	cells.	This	sequential	antibody	strategy,	combining	a	tumor-targeting	
antibody	with	a	second	antibody	that	activates	the	host	innate	immune	system,	may	improve	the	therapeutic	
effects	of	antibodies	against	breast	cancer	and	other	HER2-expressing	tumors.
Introduction
Of the 207,000 women diagnosed with breast cancer in the 
United States in 2010, one-fourth had tumors overexpressing 
the transmembrane receptor tyrosine kinase human epidermal 
growth factor receptor 2 (HER2; also known as HER-2/neu). 
These women comprise a disproportionate number of the 40,000 
annual breast cancer deaths. Trastuzumab is a humanized mAb 
targeting HER2. Despite improving the outcome for this poor-
prognostic group of patients, response rates in metastatic breast 
cancer to trastuzumab as monotherapy are limited, consisting of 
approximately 10%–15% (1).
Multiple strategies have been investigated to enhance the anti-
tumor activity of trastuzumab, which is due, at least in part, to 
antibody-dependent cellular cytotoxicity (ADCC) (2–5). ADCC is 
dependent upon immune effector cells, mainly NK cells, binding 
via their Fc receptor (FcγRIII, CD16) to the IgG1 Fc, heavy-chain 
portion of trastuzumab (3). This leads to the activation of the NK 
cells, release of their cytotoxic granules, and lysis of the trastuzum-
ab-bound breast cancer cell (6). Clinical results have shown that 
patients harboring an FcγRIIIA polymorphism with higher NK 
affinity for IgG1 have a better response to trastuzumab, further 
supporting the hypothesis that ADCC, including its mediators, 
is an important in vivo mechanism of trastuzumab action (7, 8). 
Additional supporting clinical data demonstrated that responders 
to neoadjuvant trastuzumab exhibited a 4-fold increase in anti-
body-dependent lytic activity from isolated PBMCs compared with 
that of nonresponders (4). Therefore, augmenting ADCC could 
increase the clinical efficacy of trastuzumab therapy.
Selectively targeting activated NK cells at the tumor site would be 
an attractive strategy to improve ADCC without incurring the sys-
temic toxicity of global NK cell stimulation, such as that observed 
with systemic IL-2 or IL-12 (9, 10). Recently, it was shown that 
human NK cells upon Fc-receptor triggering, such as the interac-
tion with antibody-bound tumor cells, upregulate the inducible 
costimulatory molecule CD137 (11). Once induced to express 
CD137, we hypothesize that the killing function of these activated 
NK cells can be enhanced by their exposure to an agonistic mAb 
against CD137, leading to improved antitumor activity. In the cur-
rent study, we investigate the hypothesis that an agonistic mAb 
against CD137 can enhance the killing of human breast cancer 
cells by trastuzumab both in vitro and in vivo.
Results
Human HER2-expressing tumor cells coated with trastuzumab induce 
the expression of CD137 on human NK cells. Purified NK cells from 
healthy human subjects were incubated with trastuzumab and 
breast cancer cell lines (BT474M1, HER18, or SKBR3) expressing 
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HER2. This resulted in robust upregulation of CD137 expres-
sion. In contrast, incubation of the same human NK cells in 
the absence of tumor cells or in the presence of HER2-express-
ing tumor cells and a nonbinding mAb (rituximab) had little 
effect on CD137 expression (Figure 1A). No induction of CD137 
occurred on NK cells following incubation of breast cancer cell 
lines with trastuzumab in the presence of a breast cancer cell 
line that does not overexpress HER2 (MCF7) (Figure 1, A and 
B). Similarly, trastuzumab D265A, a trastuzumab variant that 
does not bind human FcγRs, abrogated the increase in CD137 
expression on NK cells following exposure to trastuzumab-coat-
ed HER2-expressing tumor cells (Supplemental Figure 1; supple-
mental material available online with this article; doi:10.1172/
JCI61226DS1). CD137 upregulation occurred preferentially 
among CD56dim in comparison with CD56hi NK cells (Figure 1C). 
The induction of CD137 peaked after 24 hours and was associat-
ed with a concurrent decrease in the expression of FcγRIII (CD16) 
(Figure 1C). Despite a similar decrease in NK cell expression of 
CD16 following culture with trastuzumab-bound HER2-express-
ing tumor cells (Supplemental Figure 2A), NK cells from healthy 
donors with high-affinity polymorphisms of FcγRIIIA-158 
(V/V or F/V) expressed increased levels of CD137 compared with 
NK cells from donors with a low affinity FcγRIIIA-158 (F/F) poly-
morphism (Supplemental Figure 2B).
An agonistic anti-CD137 mAb increases trastuzumab-mediated NK 
cell cytokine secretion and trastuzumab-dependent NK cell–mediated 
cytotoxicity. NK cells from healthy donors were cocultured with trastu-
zumab-bound HER2-expressing breast cancer cells for 24 hours. 
Subsequently, the activated NK cells were reisolated and combined 
with breast cancer cells under different antibody conditions. The 
function of these activated NK cells was investigated by measur-
ing secretion of IFN-γ and lysis of breast cancer cells. Anti-CD137 
agonistic mAb significantly increased trastuzumab-induced IFN-γ 
secretion when incubated with 2 of 3 HER2-overexpressing breast 
cancer cell lines (SKBR3 and HER18) (Figure 2, A–D). Moreover, 
the anti-CD137 mAb enhanced the ability of these activated NK 
cells to kill trastuzumab-coated tumor cells (Figure 2, E–H). Anti-
CD137 mAb alone had minimal effect in the absence of both 
trastuzumab and HER2-overexpressing breast cancer cells. To 
confirm the enhanced cytotoxicity, 51Cr-labeled breast cancer cell 
lines were cultured with NK cells, both unpurified (Supplemental 
Figure 3) and purified (Figure 3, A–D), following activation in the 
Figure 1
Trastuzumab induces CD137 
upregulation on human NK 
cells following exposure to 
HER2-overexpressing tumor 
cells. Purified NK cells from 
the peripheral blood of 3 
healthy donors were ana-
lyzed for CD137 expression 
after 24-hour culture with 
breast cancer cell lines or no 
tumor and IgG control, ritux-
imab, or trastuzumab. (A) 
Percentage of CD137+ cells 
among CD3–CD56+ NK cells 
from 3 healthy donors cul-
tured with MCF7, BT474M1, 
HER18, and SKBR3 breast 
cancer cell lines. *P = 0.046; 
**P < 0.001. Data are shown 
as mean ± SEM. (B) HER2 
surface expression on breast 
cancer cell lines, with his-
tograms colored according 
to the log10-fold increase in 
MFI of breast cancer cell line 
relative to isotype. (C) CD137 
and CD16 expression on NK 
cell subsets CD3–CD56bight 
and CD3–CD56dim from a 
representative healthy donor 
after 24-hour culture with IgG 
control alone, HER18 and IgG 
control, HER18 and rituximab, 
or HER18 and trastuzumab. 
Percentages of total NK cells 
per quadrant are indicated.
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presence or absence of trastuzumab and anti-CD137 mAb. Again, 
the combination of anti-CD137 antibodies with trastuzumab 
induced enhanced ADCC relative to treatment with trastuzumab 
alone using both unpurified and purified NK cells. This effect 
was observed only against HER2-overexpressing breast cancer cell 
lines, confirming that the killing was due to ADCC, even though 
the NKs had been preactivated.
To investigate whether augmented antibody-mediated 
cytotoxicity of activated NK cells is restricted to the antibody-
coated tumor cell used for NK cell activation, cytotoxicity against 
HER2-expressing breast cancer and CD20+ lymphoma cells was 
compared using NK cells activated by trastuzumab-coated breast 
cancer or rituximab-coated lymphoma cells. Activated NK cells 
lysed antibody-coated tumor cells with augmented cytotoxicity 
independently of antibody-coated tumor cells used for activation. 
Anti-CD137 mAbs significantly increased trastuzumab-mediated 
breast cancer cytotoxicity of NK cells activated by culture with 
either trastuzumab-coated breast cancer or rituximab-coated lym-
phoma cells (Supplemental Figure 4, A–D). Similar enhancement 
of rituximab-mediated lymphoma cytotoxicity was observed using 
Figure 2
Anti-CD137 agonistic mAbs increase trastuzumab-mediated NK cell cytokine secretion and cytotoxicity on tumor cells as assayed by cell viability. 
To evaluate NK cell function, purified NK cells were isolated from 3 independent, healthy donor PBMCs and cultured for 24 hours together with 
trastuzumab (10 μg/ml) and irradiated (50 Gy) breast cancer cells (SKBR3) at a ratio of 1:1. After 24 hours, NK cells were isolated by negative 
selection and assessed for purity (>90% purity as defined by CD3–CD56+ flow cytometry) and activation (>50% expression of CD137). Breast 
cancer cell lines including MCF7 (A and E), BT474M1 (B and F), HER18 (C and G), and SKBR3 (D and H) were cultured for 18 hours with preac-
tivated, purified NK cells in medium alone, or with anti-CD137 mAb (BMS-663513, 10 μg/ml) alone, trastuzumab (10 μg/ml) alone, or trastuzumab 
plus anti-CD137 mAbs (both at 10 μg/ml), and supernatant was harvested and analyzed by ELISA for IFN-γ (A, MCF7, P = 0.39; B, BT474M1, 
P = 0.16; C, HER18, *P = 0.017; D, SKBR3, *P = 0.034). Cells were washed and incubated with annexin V and 7-AAD to determine percent-
age of apoptotic tumor cells by annexin V and 7-AAD staining (E, MCF7, P = 0.43; F, BT474M1, *P = 0.031; G, HER18, *P < 0.001; H, SKBR3, 
*P < 0.001). Data are shown as mean ± SEM.
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NK cells activated by either trastuzumab-coated breast cancer or 
rituximab-coated lymphoma cells. Finally, to determine whether 
anti-CD137 mAbs enhance cytotoxicity in the setting of trastu-
zumab resistance, cytotoxicity against a breast cancer cell line 
intrinsically resistant to trastuzumab (with maintained expres-
sion of HER2, HCC1569) was performed with maintained efficacy 
observed (Supplemental Figure 5).
Anti-CD137 agonistic mAbs enhance anti–breast cancer activity of 
trastuzumab in vivo. The in vivo ability of anti-CD137 mAbs to 
enhance trastuzumab’s activity was tested in a xenotransplanted 
human breast cancer (BT474M1 cell line) model in athymic mice. 
These mice have fully competent NK cells, while lacking functional 
T cells. Anti-CD137 mAbs alone had no effect on tumor growth, 
while trastuzumab had a modest effect (Figure 4, A and C). We 
simultaneously explored the effect of trastuzumab and anti-
CD137 mAbs in various schedules. Since maximal upregulation 
of CD137 required 24 hours of NK cell exposure to trastuzum-
ab-coated cells in vitro, we aimed to determine the importance 
of injection sequence. Trastuzumab was injected on day 3 (after 
tumor inoculation) and anti-CD137 mAb was injected on either 
day 2, 3, or 4. Treatment was repeated in all groups 14 days fol-
lowing the first injection. Of the 3 combination sequences tested, 
trastuzumab followed by anti-CD137 mAbs resulted in the great-
est reduction in tumor size and mortality with the opposite order, 
anti-CD137 mAbs followed by trastuzumab, having the least effect 
on both tumor growth (Figure 4A) and survival (Figure 4B).
Since trastuzumab followed by anti-CD137 antibodies dem-
onstrated more potent antitumor activity in vivo, we chose this 
injection schedule for subsequent experiments. When the treat-
ment regimen was repeated weekly for 3 weeks, the combination 
treatment resulted in prolonged control of tumor growth and a 
significant improvement in survival (Figure 4, C and D).
Enhancement of the therapeutic activity of trastuzumab by anti-CD137 
mAb is specific to HER2-expressing tumors. To determine whether the 
synergy between anti-HER2 and anti-CD137 mAbs requires spe-
cific recognition by the antitumor antibody, 2 tumors differing 
in HER2 expression were inoculated s.c. in individual mice. On 
the left flank, mice were inoculated with MCF7 cells, which are 
HER2 low to negative. On the right flank, mice were inoculated 
with HER18 cells, a transduced derivative of MCF7 cells that sta-
bly overexpress HER2 (Figure 5A and ref. 12). Mice then received 
either trastuzumab monotherapy on day 3 or the combination 
Figure 3
Anti-CD137 agonistic mAb increases trastuzumab-medi-
ated NK cell cytotoxicity on tumor cells as assayed by 
chromium release. To evaluate NK cell cytolytic function, 
healthy PBMCs were cultured for 24 hours together with 
trastuzumab (10 μg/ml) and irradiated (50 Gy) breast can-
cer cells (SKBR3) at a ratio of 1:1. After 24 hours, NK 
cells were isolated by negative selection and assessed 
for purity (>90% purity as defined by CD3–CD56+ flow 
cytometry) and activation (>50% expression of CD137). 
Chromium-labeled breast cancer cell lines including MCF7 
(A), BT474M1 (B), HER18 (C), and SKBR3 (D) were cul-
tured for 4 hours with preactivated, purified NK cells in 
medium alone or with anti-CD137 mAbs (BMS-663513, 
10 μg/ml) alone, trastuzumab (10 μg/ml) alone, or trastu-
zumab plus anti-CD137 mAbs. Shown are percentages of 
lysis of target cells by chromium release at varying effector 
(activated NK cells)/target cell ratios cultured with medium 
alone (circles), anti-CD137 (inverted triangles), trastuzum-
ab (triangles), or trastuzumab and anti-CD137 (squares) 
antibodies (A, P = 0.67; B, *P = 0.006; C, *P = 0.041; D, 
*P = 0.031). Data are shown as mean ± SEM.
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of trastuzumab on day 3 and anti-CD137 mAb on day 4. This 
sequential therapy was repeated weekly for 3 successive weeks. 
As expected, only the HER2-overexpressing tumors responded 
to monotherapy with trastuzumab. The addition of anti-CD137 
mAbs resulted in an enhanced therapeutic effect, but only against 
the HER2-positive tumor that could be targeted by the anti-HER2 
mAbs (Figure 5, B and C).
Anti-CD137 mAbs enhance the therapeutic activity of trastuzumab against 
a human HER2-overexpressing primary breast tumor. Since the combi-
nation of trastuzumab and anti-CD137 antibodies demonstrated 
increased efficacy against HER2-overexpressing cell lines, we next 
aimed to assess efficacy of the combination therapy using a pri-
mary patient xenotransplant model. A primary HER2-overexpress-
ing breast tumor was successfully engrafted into sublethally irradi-
ated SCID mice. After tumors 
were established, the mice 
were randomized into treat-
ment groups that received one 
of the following: rat IgG con-
trol, trastuzumab, anti-CD137 
mAb, or trastuzumab followed 
24 hours later by anti-CD137 
mAb and repeated weekly for a 
total of 3 weeks. The combina-
tion of trastuzumab and anti-
CD137 mAbs was superior to 
trastuzumab alone, signifi-
cantly reducing tumor growth 
and prolonging survival (Fig-
ure 5, D and E).
Increased expression of CD137 
on circulating NK cells in patients 
receiving trastuzumab therapy. 
We identified 11 patients with 
HER2-expressing breast cancer 
receiving trastuzumab therapy. 
PBMCs were isolated prior to 
and following treatment. Sam-
ples were collected at 4 hours, 
24 hours, and 7 days follow-
ing completion of trastu-
zumab infusion (Figure 6A). 
Reduced expression of CD16hi 
and increased CD137 expres-
sion at short interval time 
points (24 hours) coincided 
with a transient loss of circu-
lating NK cells. Seven days fol-
lowing trastuzumab infusion, 
the percentage of PBMCs that 
were circulating NK cells as 
well as expression of CD16 
and CD137 were similar to 
baseline. Across the 11-patient 
cohort, the mean NK cell 
CD137 expression level at 
baseline, 4.4%, was similar at 
4 hours after trastuzumab 
infusion, 4.9%, with a gradual, 
but significant, increase in 
CD137 expression at 24 hours, 9.6% (Figure 6B). Grouping all 
post-trastuzumab infusion samples in comparison with baseline, 
NK cell CD137 expression increased approximately 2-fold. Inter-
estingly, the greatest magnitude of increase in CD137 expression 
occurred in 2 patients receiving their first doses of trastuzumab.
Discussion
One in 5 women with HER2-overexpressing breast cancer will 
relapse despite trastuzumab therapy (13). To address this, multiple 
strategies have been investigated to enhance trastuzumab’s activity 
and circumvent resistance (14, 15). Strategies currently in various 
stages of clinical testing have included a small molecule tyrosine 
kinase inhibitor, generation of bispecific antibodies, antibody-
toxin conjugates, dimerization and sheddase inhibitors, and HER2 
Figure 4
Anti-CD137 agonistic mAbs enhance anti–breast cancer activity of trastuzumab in vivo. nu/nu mice were inoc-
ulated with 5 × 106 BT474M1 breast tumor cells, s.c., on the abdomen 1 day after s.c. injection of 0.72 mg/60 d 
release β-estradiol pellet (A–D). (A and B) After tumor inoculation, mice received 2 cycles of treatment sepa-
rated by 14 days with either rat IgG control on days 3 and 17 (circles), trastuzumab antibody on days 3 and 17 
(squares), trastuzumab antibody on days 3 and 17 and anti-CD137 antibody on days 2 and 16 (diamonds), 
trastuzumab antibody on days 3 and 17 and anti-CD137 antibody on days 3 and 17 (inverted triangles), or 
trastuzumab antibody on days 3 and 17 and anti-CD137 antibody on days 4 and 18 (triangles). Mice (10 per 
group) were then monitored for tumor growth (A, *P < 0.001) and overall survival (B, *P = 0.001). (C and 
D) To determine efficacy of increased frequency of treatment using the superior combination regimen, mice 
received 3 weekly treatments with either rat IgG control starting on day 3 (circles), trastuzumab antibody 
starting on day 3 (squares), anti-CD137 antibody starting on day 4 (diamonds), or trastuzumab antibody start-
ing on day 3 and anti-CD137 antibody starting on day 4 (triangles) with treatment repeated weekly for a total 
of 3 weeks. Mice (10 per group) were then monitored for tumor growth (C, *P < 0.001) and overall survival 
(D, *P = 0.003). Data are shown as mean ± SEM.
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vaccines (16–20). Here, we present an alternative approach aiming 
at enhancing trastuzumab-mediated ADCC by stimulation of NK 
cells with an anti-CD137 agonistic mAb. Our results support the 
following therapeutic strategy. First, trastuzumab localizes to the 
site of the tumor and activates surrounding NK cells via Fc-FcγR 
interaction, which increases NK cell expression of CD137. Subse-
quent administration of an anti-CD137 agonistic mAb stimulates 
the activated NK cells to enhance their cytotoxic function while 
maintaining specificity to lysis of trastuzumab-bound, HER2-
overexpressing tumor cells.
CD137 is an inducible, costimulatory molecule expressed on 
activated CD4 and CD8 T cells, with the majority of prior work 
focusing on the use of CD137 mAbs or ligands to increase the pro-
liferation and survival of T cells (21). Impressive preclinical activity 
has been documented with anti-CD137 antibodies in solid tumor 
models, including breast cancer, sarcoma, glioma, colon carcinoma, 
myeloma, and mastocytoma. These results have motivated clinical 
trials of agonistic anti-CD137 mAb monotherapy (21–23). CD137 
expression, however, is also observed on NK cells, monocytes, den-
dritic cells, and nonhematopoietic cells, where it has only recently 
been demonstrated to have functional significance (24, 25). We have 
previously shown that the antilymphoma activity of anti-CD137 
agonistic mAb monotherapy requires both CD8 T cells and NK cells 
(26). Although in the setting of acute myeloid leukemia, expression 
of CD137 ligand by the leukemic blasts has been shown to impair 
NK cell spontaneous cytotoxicity (27), additional mouse and human 
studies have observed enhanced NK cell function, including survival 
and spontaneous cytotoxicity against both hematopoietic and solid 
Figure 5
Anti-CD137 agonistic mAb enhances anti–breast cancer activity of trastuzumab in vivo while retaining HER2 specificity against HER2-over-
expressing breast cancer cell lines and a primary breast tumor. nu/nu mice were inoculated with 5 × 106 MCF7 breast tumor cells s.c. on the 
left flank and 5 × 106 HER18 breast tumor cells s.c. on the right flank (A). (A–C) After tumor inoculation, mice received either trastuzumab on 
day 3 or trastuzumab on day 3 and anti-CD137 antibody on day 4, with each treatment repeated weekly for a total of 3 weeks. (B) Mice (10 per 
group) were monitored for tumor growth of MCF7 on the left flank (white circles) and HER18 on the right flank (white squares) when treated with 
trastuzumab, and MCF7 on the left flank (black circles) and HER18 on the right flank (black squares) when treated with trastuzumab and anti-
CD137 mAbs (*P < 0.001). (C) Representative mice (3 of 10 per group) at 25 and 50 days after tumor inoculation. SCID mice were inoculated 
with 1 × 106 HER2+ primary breast tumor cells (SU-258) by intramammary injection 24 hours after 200 cGy total body irradiation (TBI). (D and 
E). On day 40, mice were randomized to 1 of 4 groups (5 mice per group) including IgG control with treatment on day 40 (circles), trastuzumab 
on day 40 (squares), anti-CD137 mAbs on day 41 (diamonds), or trastuzumab on day 40 and anti-CD137 mAbs on day 41 (triangles). Treatment 
was repeated weekly in each group for a total of 3 treatments. Mice were monitored for tumor growth (D, *P = 0.016) and overall survival (E, 
*P = 0.002). Data are shown as mean ± SEM.
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tumors (28–31). We recently reported that rituximab-induced ADCC 
of CD20-expressing lymphoma could be augmented by anti-CD137 
agonistic mAbs in multiple mouse models (32).
We show that exposure of human NK cells to 
trastuzumab-bound, HER2-overexpressing breast 
cancer results in marked CD137 expression, depen-
dent upon and influenced by the affinity of Fc-FcγR 
binding. Our findings support prior studies using 
immobilized IgG1- or rituximab-coated lymphoma 
cells to induce CD137 expression (11, 32). Notably, 
CD137 induction occurs predominantly among 
the CD56dim subset of NK cells known to mediate 
ADCC, compared with CD56hi NK cells, which are 
responsible for secretion of cytokines such as IFN-γ 
(33). We observed a concurrent downregulation 
of CD16 among the CD56dim subset, supporting 
the internalization of the FcγR following Fc-FcγR 
binding (34, 35). FcγRIII polymorphisms predicted 
amplitude of CD137 upregulation, with increased 
CD137 expression following Fc-FcγR binding of 
high-affinity polymorphisms. In vivo, we expect 
NK cells in contact with trastuzumab-bound tumor 
cells to be activated regardless of anatomic site, such 
as within the primary tumor, tumor-involved lymph 
nodes, or at distant sites of metastatic breast cancer. 
In a small series of peripheral blood patient samples 
obtained prior to and following trastuzumab, down-
regulation of CD16 and increased expression of 
CD137 occurred approximately 4 to 24 hours after 
trastuzumab infusion, with marked heterogeneity 
in magnitude of change. Timing after trastuzumab 
infusion, prior exposure to trastuzumab, burden of 
disease, and genetic polymorphism of FcγRIIIa may 
contribute to the heterogeneity. As efficacy of anti-
CD137 mAb is partially dependent upon expression 
of CD137 on NK cells, the magnitude and timing of 
CD137 expression in the peripheral blood or at the 
tumor site following antibody therapy may provide 
a predictive biomarker of response.
CD137 stimulation of NK cytotoxicity is restrict-
ed to HER2-overexpressing tumors by 2 mecha-
nisms. First, CD137 upregulation requires contact 
with trastuzumab-coated tumor cells. For instance, 
HER2-negative tumor and/or irrelevant antitu-
mor mAbs do not induce upregulation of CD137 
on NK cells. Second, CD137 stimulation of acti-
vated (CD137 expressing) NK cells only enhances 
cytotoxicity toward mAb-coated tumor cells and 
not uncoated tumor cells. This explains why the 
enhanced functional activity we observed following 
in vitro and in vivo stimulation of activated NK cells 
with anti-CD137 agonistic mAbs maintained speci-
ficity to HER2-overexpressing tumors, including in 
an in vivo, 2-tumor model. This may translate to a 
clinical benefit in reduced toxicity of the combina-
tion antibody approach, as systemic NK cell stimu-
lation should not be expected. Current therapies 
such as high-dose IL-2, though clinically benefi-
cial, are limited by systemic toxicity (36, 37). Other 
approaches, such as IL-12 or blockade of inhibitory 
KIR receptors, similarly are unable to selectively target NK cells 
implicated in trastuzumab-mediated tumor cell killing (36, 38, 39). 
In the approach developed here, we expect anti-CD137 mAbs to 
Figure 6
Increased expression of CD137 on circulating NK cells in patients receiving trastu-
zumab therapy. PBMCs were isolated from 11 patients with HER2-expressing breast 
cancer prior to and following trastuzumab treatment. (A) CD56 and CD3 expres-
sion on circulating lymphocytes and CD16 and CD137 expression on NK cell sub-
sets CD3–CD56bight and CD3–CD56dim from a single representative patient at 3 time 
points, including prior to trastuzumab, and 24 hours and 7 days following trastuzum-
ab. (B) Percentage of CD137+ cells among circulating CD3–CD56+ NK cells from 11 
patients prior to and following trastuzumab, including 2 patients receiving their first 
dose of trastuzumab (patients 18345.BR.001 [white circles] and 18345.BR.006 [white 
squares]). Data are shown as mean ± SEM.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 122   Number 3   March 2012 1073
preferentially target activated NK cells (i.e., expressing CD137), 
including NK cells implicated in tumor-directed ADCC while 
sparing inactive or resting NK cells, thereby limiting potential off-
target toxicity of anti-CD137 mAbs.
In addition to dependence on trastuzumab and HER2-overex-
pressing breast cancer, the combination approach required proper 
sequence of antibody administration to demonstrate significant 
enhancement of trastuzumab’s activity. In the absence of trastu-
zumab, we did not observe any level of anti–breast cancer activity 
of anti-CD137 mAbs either directly or indirectly by stimulation 
of NK cells in vitro or in vivo. If the murine model recapitulates 
the human clinical setting, at least in part, then determining this 
interval between antibodies is critical. Though a 24-hour inter-
val allowed for peak CD137 expression in vitro following NK cell 
exposure to trastuzumab, based on the first 11 patients assessed 
prior to and following trastuzumab, the kinetics of CD137 expres-
sion are heterogeneous. Accrual of additional patients in the study 
of CD137 levels may identify the predictive factors. However, if 
current demographic and clinical-pathologic characteristics do 
not fully explain the variance, then administration of anti-CD137 
mAbs could be individually tailored to the time point of maximal 
CD137 expression following trastuzumab.
To limit the potential effector cells responsible for breast cancer 
cell lysis, we used purified NK cells in vitro and, in vivo, partially 
immunodeficient mouse models. The nu/nu and SCID mice are 
both competent in NK cells and macrophages and complement 
but lack a functional adaptive immune response. However, mAbs 
targeting CD137 in vivo likely influence the function of multiple 
cell types, including hematopoietic cells such as granulocytes, T 
cells, B cells, dendritic cells, and monocytes, in addition to NK 
cells, as well as nonhematopoietic cells (25, 40–43). In particular, 
our partially immunodeficient mouse models do not explore the 
impact of trastuzumab and anti-CD137 combination therapy on 
the adaptive immune response. This may be of importance, as we 
previously observed in an immunocompetent mouse model of 
lymphoma that anti-CD137 mAbs resulted in the generation of 
immune memory, as illustrated by protection from rechallenge 
(32). Recently, Bellati et al. detailed the importance of the adaptive 
immune response to trastuzumab therapy in its clinical efficacy 
(44). Taken together, we hypothesize that anti-CD137 agonistic 
mAbs following trastuzumab may also improve adaptive immu-
nity in addition to enhancing ADCC. This hypothesis is supported 
by recent work by Stagg et al. (45). Recognizing that anti-CD137 
mAbs enhance both adaptive and innate immune responses, Fc 
engineering may further improve efficacy by optimizing the bind-
ing to FcRIIB, recently recognized to be necessary for anti-TNFR 
mAbs’ agonistic effects on adaptive immunity (46). Stimulation of 
CD137-expressing non-NK cells may also induce toxicity, includ-
ing off-target hepatocyte toxicity due to CD8 T cell–dependent 
hepatitis, which has been observed in both mouse models and a 
phase I clinical trial of anti-CD137 monotherapy (47, 48). How-
ever, given the synergy between trastuzumab and anti-CD137 
mAbs, combination with a tumor-directed mAb may allow the use 
of minimal doses of anti-CD137 mAbs, limiting toxicities while 
retaining antitumor activity.
An area worthy of further investigation is the setting of CD137 
stimulation in trastuzumab resistance. Clinical studies have been 
unable to demonstrate decreased HER2 receptor levels or blocked 
trastuzumab-binding capacity among patients with trastuzumab-
resistant disease (4, 49). Using a cell line with intrinsic resistance to 
trastuzumab, without loss of surface HER2 expression and due to 
either expression of t-DARPP (50) or E-cadherin (51), we observed 
preserved ability of anti-CD137 mAbs to enhance trastuzumab-
dependent cytotoxicity. Therefore, even in instances of diminished 
response to trastuzumab, enhancing ADCC with CD137 stimula-
tion may offer the opportunity to overcome tumor resistance.
In conclusion, the results of our study demonstrate that anti-
CD137 mAbs can enhance trastuzumab’s activity by stimulat-
ing the immune response to trastuzumab-bound, HER2-over-
expressing breast cancer in vitro and in xenotransplant models. 
This approach is dependent upon sequential targeting first of the 
tumor by trastuzumab and second of the activated NK cells by 
anti-CD137 agonistic mAbs. This antibody strategy targeting both 
the tumor and the immune system may thus offer new opportuni-
ties to enhance the efficacy of therapeutic antibodies in cancer. 
This approach is widely applicable across cancers, including to 
known antibodies and known antigen-expressing tumors, such as 
rituximab and CD20-expressing lymphomas (32) and cetuximab 
and EGFR-expressing head and neck as well as colorectal tumors 
and to yet undeveloped antibodies to currently unknown tumor 
antigens. Clinical investigations are now warranted to determine 
whether this hypothesis holds true in patients.
Methods
Cell lines and culture. The human breast cancer cell lines BT474M1 and HER18 
were obtained from Byron Hann at UCSF (San Francisco, California, USA). 
MCF7 and SKBR3 were obtained from James Ford at Stanford University. 
HCC1569, a HER2-expressing, trastuzumab-resistant breast cancer cell 
line, was obtained from Byran Hann at UCSF. The human CD20-positive B 
cell line, Raji, was obtained from ATCC. The SKBR3 cell line was cultured 
in McCoy’s 5A modified medium (Life Technologies; Invitrogen) supple-
mented with 10% heat-inactivated FCS (HyClone Laboratories), 100 U/ml 
penicillin, and 100 μg/ml streptomycin (both from Life Technologies; 
Invitrogen). The MCF7 and BT474M1 cell lines were cultured in DMEM 
medium (Life Technologies: Invitrogen), Raji cell line was cultured in RPMI 
(Life Technologies; Invitrogen), and the HCC1569 and HER18 cell lines 
were cultured in DMEM/F12 1:1 medium (Life Technologies; Invitrogen), 
all supplemented as above. Cells were grown as adherent cultures at 37°C 
in 5% CO2 and passaged after detachment by 0.05% trypsin (Life Technolo-
gies; Invitrogen). MCF7, BT474M1, HER18, and SKBR3 express minimal, 
moderate, and high levels of HER2, respectively, with specific fluorescence 
indices (tumor MFI/isotype MFI) of 0.17, 1.24, 1.54, and 1.62. These cell 
lines express neither the CD137 ligand nor the CD137 receptor.
Mice. Five- to six-week-old female athymic (nu/nu) nude Foxn1nu and 
SCID mice (Prkdcscid) were purchased from Harlan and Jackson Laborato-
ries and were housed at the Laboratory Animal Facility at the Stanford 
University Medical Center.
Therapeutic antibodies. Rat anti-mouse CD137 (4-1BB) mAb (IgG2a, clone 2A; 
ref. 52) was produced from ascites in SCID mice as previously described 
(25, 26). Control rat IgG was obtained from Sigma-Aldrich. Human anti-
human CD137 mAb (BMS-663513, IgG4) was provided by Bristol-Myers 
Squibb. Rituximab, (murine-human chimeric anti-CD20, IgG1), trastu-
zumab (humanized anti-human epidermal growth factor receptor-2, IgG1), 
and trastuzumab D265A (variant of trastuzumab with a single alanine sub-
stitution that impairs binding of trastuzumab in all human FcγR; ref. 3) 
were obtained from Genentech.
CD137 expression on human NK cells from patient samples and healthy individuals. 
PBMCs, which were obtained from the Stanford Blood Center, were iso-
lated from patients with HER2/neu+ breast cancer at 2 or 3 time points 
and from healthy donors by density gradient separation using Ficoll-Paque 
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PLUS (Amersham Biosciences). PBMCs from patients with HER2/neu+ 
breast cancer at time points, including immediately before and either 4, 24, 
or 168 hours after trastuzumab infusion, were assayed for NK cell expres-
sion of CD137 and CD16. PBMCs isolated from healthy individuals or 
purified NK cells isolated by negative magnetic cell sorting using NK cell 
isolation beads (Miltenyi Biotec) were cultured, 1:1, in complete medium 
for 24 hours with breast cancer cell lines in the presence of rituximab, 
trastuzumab (10 μg/ml), or trastuzumab-D265A (10 μg/ml). Assessment 
of CD137 and CD16 expression on NK cells was performed in triplicate for 
each of 3 healthy individuals.
In vitro NK functional assays. PBMCs or purified NK cells were incubated 
for 24 hours with irradiated (50 Gy) HER2-expressing breast cancer cells 
(SKBR3 or HER18 or HCC1569) at a ratio of 1:1 and with trastuzumab 
(10 μg/ml). Following 24-hour culture of PBMCs with irradiated breast 
cancer cells, purified NK cells were then isolated by negative magnetic cell 
sorting using NK cell isolation beads (Miltenyi Biotec) according to the 
manufacturer’s instructions and to greater than 90% purity, as defined 
by CD3–CD56+ and confirmed by flow cytometry. Activation of NK cells 
was confirmed by flow cytometry (>50% expression of CD137). The acti-
vated NK cells were then cultured with additional breast cancer cell lines 
(MCF7, BT474M1, HER18, SKBR3, or HCC1569) at a ratio of 1:1. After 
18 hours, the supernatants were removed and assayed for IFN-γ by ELISA 
(human IFN-γ BD OptEIA ELISA Set and BD OptEIA Reagent Set B; BD 
Biosciences — Pharmingen). Cells from these cultures were incubated with 
FITC–annexin V and 7-AAD (both BD Biosciences) and analyzed by flow 
cytometry. Forward and side scatter were used to gate out the NK cells, and 
fluorescence was used to determine the percentage of apoptotic tumor cells 
by annexin V and 7-AAD staining. NK cell cytotoxicity was additionally 
measured by a chromium release assay (53): target tumor cells were labeled 
with 150 μCi 51Cr per 1 × 106 cells for 2 hours. Both activated purified 
and nonpurified NK cells were prepared as described above and were then 
added at variable effector/target cell ratios from 1:1 to 50:1. Percentage of 
lysis was determined after 4 hours of culture in the presence of anti-CD137 
mAbs (BMS-663513, 10 μg/ml) alone, trastuzumab (10 μg/ml) alone, or 
trastuzumab plus anti-CD137 mAbs (both at 10 μg/ml). All assays were 
performed in triplicate with 3 independent NK cell samples.
Tumor transplantation and antibody therapy. BT474M1 breast cancer cells 
were implanted s.c. into 5- to 6-week-old female athymic nu/nu mice at a 
dose of 5 × 106 cells in 50 μl of PBS mixed with 50 μl of Matrigel (BD Bio-
sciences) 1 day after s.c. implantation of a 0.72 mg/60 d release β-estradiol 
pellet (Innovative Research of America). mAbs were administered by i.p. 
injections. Trastuzumab was given i.p. at 120 μg/injection, and anti-CD137 
mAb was given i.p. at 150 μg/injection at various times after tumor inocu-
lation. To determine the HER2 specificity of the therapy, nu/nu mice were 
inoculated with 5 × 106 HER18 (HER2 overexpressing) breast tumor cells, 
s.c., on the right flank, and 5 × 106 MCF7 (HER2 not overexpressing) breast 
tumor cells, s.c., on the left flank. Trastuzumab and anti-CD137 mAbs 
were administered after tumor inoculation as above. Tumor growth was 
measured by caliper twice a week and expressed as the product of length 
by width in square centimeters. Mice were sacrificed when tumor size 
reached 4 cm2 or when tumor sites ulcerated. All in vivo models were pilot-
ed with 5 mice per group and repeated with 10 mice per group (Figure 4, 
A–D, and Figure 5, A–C).
Primary breast cancer xenotransplant model and antibody therapy. Primary 
breast tumor tissue was obtained with informed consent from patients 
in accordance with the Declaration of Helsinki and study approval by 
Stanford University’s Administrative Panels on Human Subjects. SU-258 
was obtained from a primary tumor diagnosed as HER2 overexpressing by 
FISH and negative for both estrogen and progesterone receptors. HER2 
overexpression was confirmed by flow cytometry with specific fluorescence 
index (tumor MFI/isotype MFI) of 1.3. SU-258 cells, 1 × 106, injected into 
5- to 6-week-old SCID mice by the intramammary route 24 hours after 
sublethal irradiation (200 cGy). On day 40, when tumor size averaged 
0.25 cm2, mice were randomized to groups of 5, each treated with trastu-
zumab followed the next day by anti-CD137 mAbs, or to control groups 
with single antibody treatments or no treatment. Treatment was repeated 
weekly in each group for a total of 3 treatments. Mice were monitored for 
tumor growth and survival as above. In vivo primary breast models were 
performed once with 5 mice per group (Figure 5D).
Antibodies for flow cytometry. mAbs to human antigens were used for stain-
ing of human PBMCs including CD16 FITC, CD137 ligand PE, CD56 PE, 
CD3 PerCP, anti-HER2/neu APC, CD137 APC, APC-H7, FITC–annexin 
V, and 7-AAD (all from BD Biosciences). Stained cells were collected on 
a FACSCalibur or a LSRII 3-laser cytometer (BD), and data were analyzed 
using Cytobank (http://www.cytobank.org) (54).
Statistics. Prism software (GraphPad) was used to analyze tumor growth 
and determine statistical significance of differences (including mean ± SEM) 
between groups by applying a 2-tailed, unpaired Student’s t test or 2-way 
ANOVA with Bonferroni’s correction for multiple comparisons. Kaplan-
Meier plots were used to analyze survival. Comparisons of survival curves 
were made using the log-rank test. P < 0.05 was considered significant. For 
tumor burdens, comparisons of means were done by ANOVA.
Study approval. Human peripheral blood and primary breast tumor sam-
ples were obtained following informed consent from patients in accordance 
with the Declaration of Helsinki by Stanford University’s Administrative 
Panels on Human Subjects (NCT01114256). All animal experiments were 
approved by the Stanford Administrative Panel on Laboratory Animal Care 
and conducted in accordance with NIH guidelines.
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